FDA drug regulator says she will scrutinize SSRIs and RSV products for babies
Tracy Beth Høeg said in her first address to staff that she will scrutinize antidepressants and RSV products used to protect babies. She said she is prioritizing the health of women and babies.
Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her first address to staff that she’ll scrutinize antidepressants and the shots used to protect babies from RSV. Høeg, the fifth director of the Center for Drug Evaluation and Research since last year, says she is prioritizing the health of women and babies.
The review focus described by Høeg centers on SSRIs and RSV monoclonals used to protect babies from RSV.